Foghorn Therapeutics (FHTX) Operating Leases (2019 - 2026)

Foghorn Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $40.1 million for Q1 2026.

• In Q1 2026, Operating Leases rose 55.92% year-over-year to $40.1 million; the TTM figure through Mar 2026 stood at $40.1 million (up 55.92% YoY), while the FY2025 annual figure was $40.3 million, up 8.66% from the prior year.
• Operating Leases was $40.1 million for Q1 2026 at Foghorn Therapeutics, down from $40.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $51.5 million in Q4 2022 to a low of $15.8 million in Q3 2025.
• Historically, Operating Leases has averaged $37.2 million across 5 years, with a median of $38.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Operating Leases sank 47.94% in 2025, then jumped 55.92% in 2026.
• A 5-year view of Operating Leases shows it stood at $51.5 million in 2022, then fell by 29.03% to $36.6 million in 2023, then increased by 1.58% to $37.1 million in 2024, then climbed by 8.66% to $40.3 million in 2025, then decreased by 0.54% to $40.1 million in 2026.
• The last three Operating Leases figures came in at $40.1 million (Q1 2026), $40.3 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.